Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis

Codreanu Catalin; Sirova Klara; Jarosova Katerina; Batalov Anastas

首页> 外文期刊>Current medical research and opinion >Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis

【24h】

Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis

机译：在治疗活性类风湿性关节炎或强直性脊柱炎的患者的真实寿命设定中，对生物仿制性英夫利昔单抗（CT-P13）的有效性和安全性评估

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Objective: To assess the effectiveness and safety of infliximab biosimilar, CT-P13, administered in a real-life setting to adult patients with active rheumatoid arthritis (RA) or ankylosing spondylitis (AS).

机译：目的：评估英夫利昔单抗生物蛋白酶CT-P13的有效性和安全性，在现实生活中给成年患者施用有活性类风湿性关节炎（RA）或强直性脊柱炎（AS）。

著录项

来源
《Current medical research and opinion》 |2018年第10期|共7页
作者
Codreanu Catalin; Sirova Klara; Jarosova Katerina; Batalov Anastas;
展开▼
作者单位

Univ Med &

Pharm Ctr Rheumat Dis Bucharest Romania;

Revmatol MU Dr Klara Sirova Sro Revmatol Ostrava Czech Republic;

Inst Rheumatol Prague Czech Republic;

Med Univ Plovdiv UMHAT Kaspela Rheumatol Plovdiv Bulgaria;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词
Infliximab biosimilar; CT-P13; Rheumatoid arthritis; Ankylosing spondylitis;

机译：英夫利昔单抗生物仿生;CT-P13;类风湿性关节炎;强直性脊柱炎;

相似文献

外文文献
中文文献
专利

1. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis [J] . Codreanu Catalin, Sirova Klara, Jarosova Katerina, Current medical research and opinion . 2018,第10期

机译：在治疗活性类风湿性关节炎或强直性脊柱炎的患者的真实寿命设定中，对生物仿制性英夫利昔单抗（CT-P13）的有效性和安全性评估
2. Striking Discrepancy in the Development of Anti-Drug Antibodies (ADA) in Patients with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) in Response to Infliximab (INF) and Its Biosimilar CT-P13 [J] . Braun Juergen, Baraliakos Xenofon, Kudrin Alex, Arthritis & rheumatology. . 2014,第12期

机译：类风湿关节炎（RA）和强直性脊柱炎（AS）对英夫利昔单抗（INF）及其生物仿制药CT-P13的抗药抗体（ADA）开发中的惊人差异
3. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study [J] . Yoo Dae Hyun, Prodanovic Nenad, Jaworski Janusz, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第2期

机译：CT-P13（BioSimilarIngiximab）在类风湿性关节炎患者中的功效和安全性：从Planetra延伸研究中的CT-P13切换到CT-P13的切换与Planetra延伸研究中的持续CT-P13的比较
4. Collecting Visual Analogue Scales and Health Assessment of Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Using an USB Controller [C] . Jaana Suhonen, Keijo Haataja, Niina Paivinen, IEEE/IFIP International Conference in Central Asia on Internet . 2008

机译：利用USB控制器收集类风湿性关节炎患者的视觉模拟规模和健康评估和强直性脊柱炎
5. The Efficacy of Therapeutic Drug Monitoring of Rheumatoid Arthritis Patients on Infliximab [D] . Abolhosn, Rania. 2018

机译：类风湿性关节炎患者治疗药物监测对英夫利昔单抗的疗效
6. Extended report: Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study [O] . Dae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, -1

机译：扩展报告：类风湿关节炎患者中CT-P13（生物仿制药英夫利昔单抗）的疗效和安全性：在PLANETRA扩展研究中从参考英夫利昔单抗转换为CT-P13与持续进行CT-P13之间的比较
7. POS0592 BIOSIMILAR INFLIXIMAB THERAPY IN RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: A LONG-TERM FOLLOW-UP STUDY ON INFLIXIMAB-NAÏVE PATIENTS AND PATIENTS SWITCHED FROM THE ORIGINATOR TO THE BIOSIMILAR CT-P13 [O] . B. Fautrel, M. Assing, N. Mammar, 2021

机译：POS0592 BioSimilar Infliximab疗法在类风湿性关节炎，强直性脊柱炎和银屑病关节炎：对富生素-Naïve患者的长期随访研究和从发起者转换为生物邮件CT-P13的患者

Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅